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ABSTRACT
Missense point mutations in the TP53 gene are fre-
quent genetic alterations in human tumor tissue and
cell lines derived thereof. Mutant p53 (mutp53) pro-
teins have lost sequence-specific DNA binding, but
have retained the ability to interact in a structure-
selective manner with non-B DNA and to act as
regulators of transcription. To identify functional
binding sites of mutp53, we established a small
library of genomic sequences bound by p53
R273H in
U251 human glioblastoma cells using chromatin
immunoprecipitation (ChIP). Mutp53 binding to
isolated DNA fragments confirmed the specificity
of the ChIP. The mutp53 bound DNA sequences
are rich in repetitive DNA elements, which are
dispersed over non-coding DNA regions. Stable
down-regulation of mutp53 expression strongly
suggested that mutp53 binding to genomic DNA is
functional. We identified the PPARGC1A and FRMD5
genes as p53
R273H targets regulated by binding to
intronic and intra-genic sequences. We propose a
model that attributes the oncogenic functions of
mutp53 to its ability to interact with intronic and
intergenic non-B DNA sequences and modulate
gene transcription via re-organization of chromatin.
INTRODUCTION
Mutations in the TP53 gene represent the most frequent
genetic alterations in a single gene in human cancer,
ranging between diﬀerent types of tumors from 10% to
70% (1). Unlike other tumor suppressor genes, which are
functionally eliminated by deletions, truncations, non-
sense mutations, or gene silencing,  80% of all TP53
alterations in human tumors are missense point mutations
resulting in the expression of a functionally altered mutant
p53 (mutp53) protein, with an exchange of a single amino
acid. Most missense point mutations ( 80%) are localized
in the central DNA-binding core domain (2,3). P53 binds
as tetramer to symmetrical DNA target sequences (p53
response elements) in a sequence- and geometry-speciﬁc
fashion (4). Experimental work (5) and molecular
dynamics simulations (4) provided evidence that muta-
tions in the core domain dramatically reduce the ability
of mutp53 proteins for sequence-speciﬁc DNA binding;
however geometry-speciﬁc DNA binding is retained and
detectable under in vitro conditions (6). In tumor cells,
mutp53 is able to regulate the expression of a large
number of tumor-associated genes (7). Although several
recent reports demonstrated that mutp53 can physically
interact with promoter regions of target genes identiﬁed
by microarray analyses (8), the molecular mechanism of
the transcriptional activity exerted by mutp53 is still far
from being understood. Two diﬀerent, but not mutually
exclusive possibilities are currently considered: (i) mutp53
interacts speciﬁcally with other transcription factors,
such as Sp1 (9), Ets1 (10) and NF-Y (11), and modulates
their activity; (ii) mutp53 has retained a residual transcrip-
tional activity from wild-type (wt) p53 (12) and modulates
transcription by interacting with components of the tran-
scription machinery. This view is supported by the ﬁnding
that the transcriptional competence of mutp53 requires
intact N-terminal (13) and C-terminal (14) domains.
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(2,3) and are crucial for interactions with proteins of tran-
scription complexes (15,16). In both cases it is assumed
that mutp53 acts within the frame of a standard mecha-
nism encompassing reactions and interactions that take
place on regulatory sequences surrounding a transcription
start site (TSS). However, the highly complex transcrip-
tional program of a cell is not only directed by binding of
regulatory proteins to promoters. Additionally, multiple
long-range interactions within the chromatin provide a
platform for higher-order levels of gene regulation that
complement the promoter-dependent mechanism by the
possibility of integrating a single gene into a gene regula-
tory network (17). Locus control regions (LCR), enhan-
cers, silencers and insulators (18–21) are examples for
functional, promoter-distant sequence elements which
are embedded into variably sized non-coding, intra- and
inter-genic DNA regions. These regions also contain the
heterogeneous family of conformation-ﬂexible DNA
sequences that represent S/MARs (Scaﬀold/Matrix
Associated Regions) (22), characterized by their strong
binding to a nuclear, salt and detergent-insoluble protein-
aceous structure (nuclear matrix or scaﬀold) (23).
Through co-operative interaction with nuclear matrix
proteins and a wealth of regulatory proteins, S/MARs
constitute nuclear matrix anchorage sites for topologically
separate, DNase I-sensitive chromatin loops, and form
organizing centers for transcription-, replication-, recom-
bination- and repair-factories (24). S/MAR sequences
exhibit a high content of repetitive DNA elements and
adopt non-B DNA conformations under favoring condi-
tions, for example under superhelical tension (25).
On the basis of the ability of mutp53 to bind in vitro
DNA sequences capable to adopt non-B DNA conforma-
tions (6), and to interact with repetitive DNA sequences
in vivo (26), we put forward the concept of mutp53 as a
nuclear component involved in transcriptional events.
This concept is strongly supported by the fact that
mutp53 behaves like a S/MAR-binding protein (27). The
murine p53
D168G/M234I protein (MethA) was found to
interact with DNA fragments from the murine immuno-
globulin heavy chain gene enhancer locus and the inter-
feron b gene locus, which exhibit properties of S/MARs,
and the binding characteristics of MethA mutp53 to these
DNA fragments were similar to that of S/MAR–DNA-
binding proteins (28). Mutp53 proteins (MethA, and
human p53
R175H, p53
R273H, p53
R273P) bind to single-
strand/double-strand DNA junctions and, by promoting
further DNA-unwinding, generate single-stranded regions
(29,30). Such a mechanism may contribute to the confor-
mational dynamics of S/MAR sequences that lead to
activation or repression of transcription.
So far, however, no genome-wide correlation between
in vivo DNA-binding of mutp53 and its transcriptional
activity has been shown. A prerequisite for establishing
such a correlation is the identiﬁcation of functional geno-
mic mutp53-binding sites, in conjunction with gene
expression analysis in the presence of mutp53 and after
shutoﬀ of mutp53 expression, e.g. by using an RNAi
approach. In the present work we combined chromatin
immunoprecipitation (ChIP) (31) with DNA cloning and
sequencing (ChIP cloning) (32) to identify functional bind-
ing sites of mutp53 and provide data supporting the pro-
posed model of mutp53 activity. As proof of principle we
established a small library of genomic sequences bound
by p53
R273H in human U251 glioblastoma cells and
conﬁrmed the speciﬁc binding of mutp53 to isolated
DNA fragments by electrophoretic mobility shift assay
(EMSA). ChIP sequences, like S/MARs, were found to
be rich in repetitive DNA sequences and dispersed over
non-coding DNA regions. Supporting speciﬁcity of
mutp53 binding, despite the small library size we found
a tendency for a local enrichment of ChIP sequences at
distinct chromosomal positions, speciﬁcally, close to genes
whose expression was aﬀected after manipulation of the
mutp53 level. Thereby, our approach led to the identiﬁca-
tion of the PPARGC1A and FRMD5 genes as targets of
mutp53. We propose that in U251 cells p53
R273H exerts a
regulatory eﬀect on gene transcription by acting as DNA/
chromatin associated factor that participates in the orga-
nization of chromatin into functional domains.
MATERIALS AND METHODS
Celllines
The human glioblastoma cell line U251 was a kind gift
from Dr Kazuo Washiyama (Brain Research Institute,
Niigata University, Japan). Mutation (R273H) in the
TP53 gene was conﬁrmed by sequencing of PCR-ampliﬁed
p53 cDNA (see Supplementary Data). Human non-small
lung carcinoma cell line H1299 (NCI-H1299) was kindly
provided by Dr Moshe Oren (The Weizmann Institute,
Israel). The cells were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) (Invitrogen GmbH,
Karlsruhe, Germany) supplemented with 10% fetal calf
serum (FCS; PAA Laboratories GmbH, Linz, Austria)
in a humid atmosphere containing 5% CO2.
Stable transfection ofshRNA expressing vectors
To obtain U251 derived clones with a stable reduction of
p53 expression, 10
6 U251 cells were transfected either with
1.8mg pSuper-p53/0.2mg pCI-neo (Oligoengine), or 2mg
pENTR/H1-p53 using the NHDF Neo kit, program U20
(Amaxa AG, Cologne, Germany) and plated into three
10cm dishes. As control for oﬀ-target eﬀects of the
shRNA, U251 cells were transfected with pENTR/H1-scr
for the expression of scrambled shRNA. To generate the
pENTR/H1-p53 and pENTR/H1-scr constructs the
respective expression cassette [see (33) and Table S8 for
sequences] were cloned into the vector backbone of
pENTR/H1/TO (Invitrogen GmbH) according to the
manufacturer’s protocol. Forty-eight hours after transfec-
tion the cell culture medium was supplemented with
0.4mg/ml G418 sulphate (PAA Laboratories GmbH) or
100mg/ml Zeocin (Invitrogen GmbH). G418- and Zeocin-
resistant clones were picked using cloning rings and
propagated for further characterization. Integration of
vectors intoU251 genomewas checked byPCR from geno-
mic DNA using vector speciﬁc primers (see Table S8).
Reduction of p53 expression in the established clones
was measured by real-time qRT–PCR, immunoblotting
Nucleic Acids Research,2009, Vol.37, No. 5 1487and immunoﬂuorescence staining. Expression of
scrambled shRNA was veriﬁed by stem-loop RT–PCR
(34) using speciﬁc primer set (see Table S8).
ChIP
Cells were cultured in three 15cm diameter tissue culture
dishes. At 80% conﬂuence, cells were treated with DMEM
supplemented with 1% formaldehyde (Sigma-Aldrich
Chemie Gmbh, Munich, Germany) for 10min at 378C.
Cells were then washed with warm PBS (pH 7.4) buﬀer,
and crosslinking was stopped by adding 125mM glycin in
PBS. Treated cells were washed twice with cold PBS, once
with KM buﬀer (10mM HEPES, pH 7.5, 10mM NaCl,
1.5mM MgCl2, 1mM EGTA, 5mM dithiothreitol,
10% glycerol), and lysed for 30min on ice in KM buﬀer
supplemented with 1% Nonidet P-40 (NP-40) and protease
inhibitors (5mg/ml leupeptin (Sigma-Aldrich), 1mg/ml pep-
statin (Sigma-Aldrich), 1% Trasylol (Bayer), 0.1mg/ml
Pefabloc SC (Biomol GmbH, Hamburg, Germany)).
After centrifugation at 900 g at 48C, the supernatant
was discarded and the pellet was slowly shaken with KM
buﬀer adjusted to 2M NaCl overnight at 48C. Finally, the
residual cell structures were harvested in TE buﬀer (10mM
Tris–HCl, pH 8.0, 1mM EDTA) and centrifuged at
15000 g for 5min. The cell pellet was resuspended in
300ml TE buﬀer and sonicated for 10min in a Bioruptor
UCD-200 (Diagenode sa, Liege, Belgium) according to the
manufacturer’s instructions. Debris was eliminated by cen-
trifugation for 20min at 20000 g at 48C. Protein concen-
tration was quantiﬁed by Bradford Assay (Bio-Rad
Laboratories GmbH, Munich, Germany). DNA size was
estimated after reverse crosslinking and DNA puriﬁcation
by agarose gel electrophoresis. Optional precipitation
with 1% N-cetyl-N,N,N,-trimethylammonium bromide
was performed (Cetavlon; Merck KGaA, Darmstadt,
Germany) to remove non-crosslinked proteins from sam-
ples as previously described (32). For immunoprecipitation
(IP), goat polyclonal (sc-6243; Santa Cruz Biotechnology,
Heidelberg, Germany) or monoclonal (DO1 and Pab421)
anti-p53 antibodies, goat polyclonal anti-lamin B antibody
(sc-6217; Santa Cruz Biotechnology), and protein
G-sepharose (GE Healthcare Europe GmbH, Munich,
Germany) were used. IP was done in 500ml reaction
volume as described elsewhere (32). Sau3A (Fermentas
GmbH, St Leon-Rot, Germany) digestion of chromatin
was conducted during the capture of immunocomplexes
on sepharose beads. Protein–DNA complexes were eluted
with 250ml elution buﬀer (0.5% SDS, 20mM Tris–HCl,
pH 8.0, 2mM CaCl2) for 15min at 658C. Supernatants
were collected and elution was repeated once more. To
reverse protein–DNA crosslinks, samples (500ml) were
supplemented with 500mg/ml Proteinase K (Roche
Diagnostics GmbH, Mannheim, Germany) and incubated
at 508C for 1h, followed by 4h at 658C. DNA was
extracted twice with phenol–chloroform–isoamylalcohol
(25:24:1; Biomol GmbH), precipitated with ethanol in
the presence of 10mg glycogen (Roche Diagnostics
GmbH), washed with 70% ethanol, air-dried and
dissolved in water. Double-stranded Sau3A-adapters
were prepared by annealing of 50phosphorylated 24-mer
and non-phosphorylated 20-mer oligonucleotides (see
Table S8). Adapters were ligated to Sau3A-cleaved immu-
noprecipitated DNA using T4 DNA ligase (New England
Biolabs GmbH, Frankfurt am Main, Germany). Adaptor-
bearing DNA molecules were ampliﬁed by PCR using
Sau3A-primer (see Table S8) under the following condi-
tions: 2min at 948C, 29 cycles (948C for 60s, 558C for
30s, 728C for 60s) and 10min at 728C. PCR products
were analyzed on a 1.5% agarose gel, puriﬁed, and either
ligated into the cloning vector pCRII applying the TA
cloning kit (Invitrogen GmbH) or cleaved with Sau3A
and ligated into the BamHI site of the pBluescript II SK
vector (Stratagene). Ligated DNA was transformed into
the competent E. coli TOP10 (Invitrogen GmbH) or
SURE (Stratagene) strain. Recombinant plasmid DNAs
were puriﬁed using NucleoSpinPlasmid (MACHEREY-
NAGEL GmbH & Co. KG, Du ¨ ren, Germany) and their
inserts were sequenced by Euroﬁns MWG Operon
(Ebersberg, Germany).
Sequence analysis
ChIP sequences were aligned with the human genome
using the BLAT algorithm (35) implemented in the
Genome browser (http://genome.ucsc.edu/index.html).
The coordinates for the highest-scoring alignments were
considered for further analysis. Randomization of chro-
mosomal coordinates was done using random package
within the R environment (http://www.r-project.org).
The length of each single chromosome (NCBI Build
36.1; hg18) was used as a range for random numbers gen-
eration. Nucleotide sequences around random positions
 1000nt were retrieved from the Genome browser data-
base. Nucleotide sequences of promoters (2000nt
upstream of TSS) for randomly selected gene accession
numbers were retrieved from the PromoSer database
(http://cagt.bu.edu/page/Promoser_submit) (36). The con-
tent of repetitive sequences was analyzed using the
RepeatMasker server (A.F.A. Smit, R. Hubley and P.
Green; http://www.repeatmasker.org/). The coordinates
of ChIP and random sequences were mapped onto the
human chromosomes using the ChromoMapper program
(http://mcluster.tu-graz.ac.at/clustercontrol/modules/
ChromoMapper/) (37). S/MAR-speciﬁc and short oligo-
meric motifs were inspected using MAR-Wiz (http://
www.futuresoft.org/MAR-Wiz) (38) and RSAT web-
tools (http://rsat.ulb.ac.be/rsat/index.html) (39), respec-
tively. P53RE was searched using PatSearch program
(http://bighost.area.ba.cnr.it/BIG/PatSearch) (40).
Electrophoretic mobility shiftassay(EMSA)
Recombinant human p53
R273H was expressed in
Escherichia coli strain C41 (DE3), derived from BL21
(DE3) using a two-step induction at 188C to limit protein
aggregation. p53
R273H was puriﬁed according to a proto-
col described previously (41) with some minor modiﬁca-
tions. In this study tetrameric form of p53 was used,
obtained by a ﬁnal puriﬁcation step by gel ﬁltration chro-
matography on Superdex HR200. Plasmid DNA was
propagated in E. coli TOP10 and puriﬁed using the
NucleoBond PC EF kit (MACHEREY-NAGEL
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with the restriction enzyme PvuII (New England Biolabs
GmbH) and puriﬁed. To perform EMSA, samples con-
taining 200ng of supercoiled plasmid DNA or PvuII-
digested plasmid DNA were incubated with p53
R273H
protein at the indicated p53 tetramer/DNA molar ratios
in binding buﬀer (5mM Tris–HCl, pH 7.6, 0.01% Triton
X-100, 0.5mM EDTA, 0.5mM DTT, 150mM KCl) for
30min on ice to reach equilibrium. After binding, samples
were supplemented with gel loading buﬀer (5 :4 0 m M
Tris–HCl, pH 7.6, 10% glycerol, 0.025% bromophenol
blue) and separated by electrophoresis on a 1% agarose
gel (Bio-Rad) in 0.33  Tris/Borate/EDTA buﬀer for
about 5h at 48C in an electric ﬁeld of 5V/cm. DNA
was stained with ethidium bromide and visualized under
UV light.
Immunofluorescence staining
Cells were plated in a six-well culture plate on glass cover-
slips at a density of 5 10
4 cells/well, ﬁxed with 4% para-
formaldehyde (PFA) in PBS and permeabilized with 1%
Triton X-100 in PBS, pH 7.4. Optionally, cells were
extracted with 1% Triton X-100 in PBS and then ﬁxed
with 4% PFA in PBS. After washing and blocking in
1% BSA/PBS, cells were stained with goat polyclonal
anti-p53 (sc-6243; FL-393) antibodies alone or in combi-
nation with rabbit polyclonal anti-SATB2 (kindly pro-
vided by Dr Victor Tarabykin, MPI for Experimental
Medicine, Go ¨ ttingen, Germany), anti-Sp1 (07-645;
Millipore GmbH, Schwalbach/Ts., Germany), anti-YY1
(sc-1703; Santa-Cruz), or anti-RNA polymerase II
(sc-899; Santa-Cruz) antibodies. Donkey anti-goat and
anti-rabbit ﬂuorochrome-coupled antibodies were
obtained from Invitrogen. The images were captured as
Z-stacks using a Plan-Apochromat 63 /1.4NA oil DIC
objective and an Axiovert 200 microscope equipped with
a LSM 510 META confocal scanner (Carl Zeiss
MicroImaging GmbH, Jena, Germany). To acquire
images of samples probed with two ﬂuorophores and
sequential scanning with DIC/transmitted light, multi-
tracking settings were used. Following image acquisition,
raw data was exported to the Huygens Essential software
(version 2.7.2p0, Scientiﬁc Volume Imaging B.V.,
Hilversum, The Netherlands) and digital deconvolution
was performed using the Maximum Likelihood
Estimation (MLE) algorithm. The restored image data
set was visualized and processed with the Imaris software
package (version 4.1.3, Bitplane AG, Zu ¨ rich, Switzerland).
Co-localization was analyzed with the ImarisColoc module
integrated into the Imaris software package, and a map of
the co-localized voxels was saved as separate channel.
Immunoblotting
Proteins were extracted by washing the cells once with
warm PBS and lysed directly in 200ml (per six wells)
of Laemmli buﬀer (62.5mM Tris–HCl, pH 6.8, 10%
glycerol, 2% SDS, 5% b-mercaptoethanol, 0.1%
bromphenol blue). Proteins were separated on SDS–
polyacrylamide gels and electroblotted onto nitrocellulose
membranes (GE Healthcare). To reverse protein–DNA
crosslinks, samples were boiled for 30min in Laemmli
buﬀer prior electrophoresis. P53, lamin B, HSC70
and actin were detected with goat polyclonal anti-p53
(sc-6243), anti-lamin B (sc-6217), anti-HSC70 (sc-1059)
and anti-actin (sc-1616) antibodies. HRP-conjugated
donkey anti-goat antibody was obtained from Santa
Cruz. Proteins were visualized using luminol-based ECL
western blotting reagent (GE Healthcare).
Expression analysis
Total RNA was isolated applying the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The quality and integrity of the total
RNA was evaluated with the 2100 Bioanalyzer (Agilent
Technologies, Waldbronn, Germany) and the concentra-
tion was measured using a NanoDrop spectrophotometer
(Peqlab Biotechnologie GmBH, Erlangen, Germany).
For microarray proﬁling on ABI human genome survey
microarray version 1 chip, biological replicates (cells at
diﬀerent passages) were prepared. The ABI human
genome survey microarray chip contained 32878 60-mer
oligonucleotide probes representing 29098 known genes.
Synthesis of cRNA, hybridization and image data proces-
sing was completed by the Core Facility at the Molecular
Diagnostic Center of the University of Muenster accord-
ing to the ABI standard protocol. Quantile normalization
was done using the limma package within the R environ-
ment. A gene was considered to be diﬀerentially expressed
between groups, if a Student’s t-test statistic had an asso-
ciated P 0.05 and a fold change (FC) 2. The microar-
ray data sets discussed in this manuscript have been
deposited in NCBI’s Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) and are accessible
through GEO series accession numbers: GSM351481,
GSM351486, GSM351488 and GSM351490.
For qRT–PCR analysis, RNA was puriﬁed using
the Trizol reagent (Invitrogen), and reverse transcribed
with the High Capacity RT kit (Applied Biosystems)
according to the manufacturer’s protocol. PCR was per-
formed using the Power SYBR Green PCR Master
Mix (Applied Biosystems) in a standard program
(10min 958C; 15s 958C, 1min 608C; 40 cycles) run-
ning in an ABI 7500 Fast thermal cycler (Applied
Biosystems). PCR reactions for each sample were repeated
in triplicates. The integrity of the ampliﬁed products was
conﬁrmed by melting-curve analysis. PCR primers were
selected from Primer Bank (http://pga.mgh.harvard.edu/
primerbank/index.html). PCR eﬃciency was measured
for each primer pair using serial dilution of cDNA. The
housekeeping gene, HPRT1, was used as endogenous con-
trol. Relative quantitation of transcript levels with respect
to the calibrator (U251 stably transfected with pENTR/
H1-scr vector) was done based on 2
 C
T algorithm (42).
RESULTS
Binding ofmutp53 tochromatin/DNA in U251cells
U251 cells express large amounts of p53
R273H which
mainly localizes to the nucleus (Figure 1A; shown in
green). There it is excluded from nucleoli and partially
Nucleic Acids Research,2009, Vol.37, No. 5 1489Figure 1. p53
R273H is targeted to the nucleus in U251 glioblastoma cells. (A–H) Confocal images of U251 cells stained with anti-p53 (green) and anti-
SATB2 (A, B), anti-Sp1 (C, D), anti-YY1 (E, F), and anti-RNA polymerase II (G, H) antibodies (red) according to a standard protocol (A, C, E,
G), or extracted with Triton X-100 prior to PFA-ﬁxation (B, D, F, H). Z-stack sections were deconvoluted using the Huygens software and the
images were processed with the Imaris software. The co-localization channel (yellow) was generated using the ImarisColoc module. Scale bar—5mm.
1490 Nucleic Acids Research, 2009, Vol. 37,No. 5co-localizes with the nuclear matrix protein SATB2 (43)
(Figure 1A; shown in red; co-localization is shown in
yellow representing 37% of red-green pixels). Extraction
of non-ﬁxed cells with the non-ionic detergent Triton
X-100, which removes most membrane lipids and soluble
proteins (44), signiﬁcantly reduced the amount of nuclear
p53
R273H. However, a small fraction of mutp53 resisted
extraction and remained bound to the detergent-insoluble
structures composed of chromatin ﬁbers and a nuclear
proteinaceous scaﬀold, represented by the SATB2 protein
(Figure 1B; 28% co-localization). The observed nuclear
punctuate distribution of detergent-resistant mutp53 and
its anchorage to the nuclear scaﬀold is reminiscent to that
of many transcription factors and of RNA polymerases
(45–47). Therefore, we tested for co-localization of
p53
R273H with the nuclear matrix-associated transcription
factors Sp1 (48) and YY1 (49), both known as binding
partners for wtp53 (50,51). Before and after Triton
X-100 extraction a fraction of mutp53 co-localized
with Sp1 and YY1 (Figure 1C–F; C—19%, D—6.5%,
E—5.7%, F—2.1% co-localization). Also immunostain-
ing with RNA polymerase II-speciﬁc antibodies revealed
co-localization with the fraction of mutp53 in punctuate
structures that resisted extraction with Triton X-100
(Figure 1G–H; G—7%, H—2.9% co-localization). We
concluded that in U251 cells a fraction of p53
R273H is
bound to components of detergent-insoluble nuclear
structures and thus could interact with genomic DNA.
To test this conclusion, we performed ChIP after form-
aldehyde crosslinking. The membrane soluble crosslinking
reagent formaldehyde produces covalent adducts of inter-
acting proteins and nucleic acids (31) by forming revers-
ible methylene bridges. In standard ChIP protocols, the
samples are submitted to the IP reaction directly after
crosslinking. However, the fraction of non-covalently
bound, i.e. non-crosslinked chromatin proteins will inter-
fere with the further procedure and lead to misinterpreta-
tion of the crosslinking eﬃciency. Therefore, we applied
the cationic detergent Cetavlon, which speciﬁcally
precipitates nucleic acids and covalently bound proteins,
and has a strong dissociating eﬀect on non-covalent
protein–nucleic-acid complexes (see Materials and
Methods section for details) (32). As shown in
Figure 2A, mutp53 as well as the chromatin-associated
protein lamin B (as a control for crosslinking) were
detected in the Cetavlon-treated DNA–protein complexes,
providing unequivocal evidence for the binding of mutp53
to chromatin in U251 cells. For the nucleotide sequence
analysis of mutp53-crosslinked DNA, we optimized the
ChIP protocol to speciﬁcally purify covalent mutp53-
chromatin complexes and thereby maximize the speciﬁcity
for LM–PCR mediated ampliﬁcation of mutp53-bound
DNA (Figure 2B). ChIP for lamin B, which has similar
DNA-binding properties as mutp53 (52,53), served as
further control for the suitability of the method. After
LM–PCR of mutp53 bound DNA fragments, followed
by agarose gel electrophoresis, a prominent broad band
representing ampliﬁed ChIP fragments could be detected
only in ChIP experiments performed with the correspond-
ing antibodies. Three diﬀerent p53 antibodies were used in
our study. The speciﬁcity of the monoclonal antibodies
DO1 and Pab421 has been already documented (54,55).
To verify the speciﬁcity of the polyclonal goat anti-p53
antibody (FL-393; Santa Cruz), a sample from p53-null
H1299 cells was processed together with a sample from
U251 cells. No visible PCR-products were detected in
the sample from H1299 cells (Figure 2C), thereby support-
ing the speciﬁcity of this p53 antibody.
AnalysisofgenomicDNAfragmentsboundbymutp53invivo
Genomic DNA fragments co-precipitated with mutp53
(ChIP sequences) were ampliﬁed by LM–PCR, cloned
and 135 randomly selected E. coli clones were picked for
plasmid puriﬁcation and sequencing. The total number of
ChIP sequences submitted to bioinformatic analysis was
165 (see Tables S1 and S2), because 30 recombinant
plasmids contained two genomic DNA fragments. The
ChIP sequences were aligned with the human genome
p53 Ab
lamin B Ab
- Ab
p53
lamin B
-cetavlon +cetavlon
AB C
U251
H1299
M M
Figure 2. Formaldehyde-mediated crosslinking of p53
R273H with genomic DNA. (A) Detection of mutp53 and lamin B by immunoblotting in
protein–DNA complexes puriﬁed from formaldehyde-treated U251 cells. DNA-bound proteins were separated by SDS–PAGE either directly or
after treatment with Cetavlon and blotted onto a nitrocellulose membrane. (B) Detection of DNA crosslinked with mutp53 and lamin B by
formaldehyde via ChIP and LM–PCR. Ampliﬁed DNA was separated by electrophoresis in an agarose gel and stained with ethidium bromide.
In the control experiment antibodies were omitted. (C) Demonstration of the speciﬁcity of the anti-p53 antibody (FL-393; Santa-Cruz). P53-deﬁcient
H1299 cells and U251 cells were treated with formaldehyde. Protein–DNA complexes were subjected to ChIP followed by LM–PCR and agarose gel
electrophoresis. M—DNA size marker.
Nucleic Acids Research,2009, Vol.37, No. 5 1491(hg18, 2006) using the Blat program (35); their coordinates
are listed in Table S2. 143 ChIP sequences were matched
to unique positions in the human genome. Two ChIP
sequences, AA23 and UC24B, were mapped to duplicated
genomic regions. The genomic position of 20 ChIP
sequences could not be ascertained because they origi-
nated from highly repetitive sequence families. Of these,
ChIP sequences UC15a and UC5 are derived from an
intact copy of long interspersed nuclear element (LINE)
and satellite II repeat DNA, respectively. Eighteen non-
identical ChIP sequences (see Figure S1, Table S1) repre-
sented beta-satellite repeat-rich chromosomal regions,
indicating a preferential binding of mutp53 to these mod-
erately repetitive sequences. The beta-satellite sequences
are composed of  69bp monomeric units, repeated in
long arrays up to 1 Mb in length and located on the
short arm of acrocentric chromosomes (56) and on some
other chromosomes (57). All ChIP sequences matching to
unique positions were inspected for the presence of repet-
itive sequences using the RepeatMasker web-program. As
the mutp53 cross-linked chromatin has been trimmed by
the four-cutter restriction enzyme Sau3A, the ﬂanking
sequences were added to the ChIP sequences to increase
the size of the inspected genomic region to 2000 nucleo-
tides (see Table S3). The content of repetitive sequences
was also determined in a set of random genomic fragments
selected as described in Methods section (2000 nucleotides
centered on randomly selected positions; see Table S4),
and randomly selected promoter regions (2kb upstream
of the TSS; see Table S5) from the PromoSer database
(36). As shown in Figure 3A, no signiﬁcant diﬀerences
were found between ChIP and random DNA datasets,
whereas LINE1 sequences were signiﬁcantly underrepre-
sented in the promoter regions, and to a lesser extent also
MaLRs, ERVLs and ERV-class I sequences.
Considering that a high content of repetitive DNA is a
hallmark of S/MAR regions, it is likely that some
mutp53-binding sites are S/MARs. As expected, both
ChIP and random sequences are distinguished from the
promoter dataset by a higher content of AT-rich motifs
(AT-richness and Ori rule) (Figure 3B). Curved-DNA and
kinked-DNA patterns show a tendency for a slight enrich-
ment within the ChIP sequences, which would support the
in vitro speciﬁcity of mutp53 for non-B DNA conforma-
tion (6). The ChIP and random datasets were also
screened for the presence of shared (conservative) motifs
(10–20 nucleotides) and the occurrence frequency of short
oligomeric sequences (6–8 nucleotides) using regulatory
sequence analysis tools (RSAT) (39). No signiﬁcant
enrichment for any motif or oligomer was detected in
both datasets (data not shown). Computational search
for the p53 Response Element (p53RE [two tandem
repeated decamers 50-PuPuPuC(A/T)(T/A)GPyPyPy-30
separated by 0–13bp]) using the PatSearch program (40)
and PatSearch syntax for the p53RE (58) also revealed no
signiﬁcant diﬀerences in the occurrence of p53RE in the
random and ChIP datasets (data not shown). These results
therefore ﬁt into our concept that the genome contains
numerous mutp53-binding sites, which are deﬁned by
structural properties rather than by primary sequence
and are diﬀerentially occupied by mutp53 in the functional
context of chromatin.
Mutp53 might either compete or cooperate with other
proteins for binding to a particular DNA site and, there-
fore, might not necessarily bind directly to DNA. To pro-
vide evidence for direct binding of mutp53 to DNA, we
analyzed a small set of ChIP sequences for in vitro binding
by recombinant bacterially expressed p53
R273H protein
applying EMSA. As the interaction of mutp53 with
DNA is structure-selective (6), it should be strongly inﬂu-
enced by alterations in DNA conformation. We therefore
compared binding of p53
R273H to ChIP sequences pre-
pared either as linear DNA or as inserts in supercoiled
pCRII vector DNA. Figure 4A shows the mobility-shift
proﬁles of EMSA performed with a mixture of PvuII
restriction fragments from control or insert-containing
pCRII vector DNA and recombinant p53
R273H at various
molar ratios. The proﬁles demonstrate that in comparison
to restriction fragments of vector DNA, ChIP sequences
showed superior binding to mutp53, although their aﬃnity
varied greatly. The strongest interaction with p53
R273H
was observed for ChIP sequence AA3. This ChIP DNA
fragment contains a 72-bp long polypurine/polypyrimi-
dine-rich region which can adopt an intramolecular
triple-helix H-DNA conformation (59). In control experi-
ments we noted that wtp53, p53
R273H and another ‘hot
spot’ DNA-binding domain mutant protein, p53
R249S,
binds to linearized AA3 and AB23 sequences with com-
parable aﬃnity, whereas the conformational mutant pro-
tein p53
R175H binds very weakly (see Figure S2). The
band-shift proﬁles in Figure 4B demonstrate that
p53
R273H binds to pCRII vector DNA in a stoichiometric
fashion, forming three slowly migrating complexes at the
highest tested protein/DNA ratio. In contrast, plasmids
containing ChIP sequences interact much stronger with
mutp53, forming multiple, slowly migrating complexes
already at a 7.5M excess of protein. Wtp53 (41,60,61)
and mutp53 (60) bind strongly to supercoiled DNA via
an interaction of the C-terminal domains of p53 tetramers
with strand crossings, thereby forming complexes with
electrophoretic properties reminiscent to the mobility of
DNA topoisomers in agarose gel. Altogether, the in vitro
binding data strongly support the notion that the ChIP
sequences reﬂect genomic DNA regions, to which
p53
R273H binds directly in U251 cells.
Functionality of mutp53-binding sites
To analyze the postulated eﬀects of mutant p53 on the
regulation of transcription, we applied shRNA-mediated
knock-down of the p53 protein level, which allows for a
comparison between parental cells and cells with
reduced p53 expression. U251 cells were transfected
with H1-promoter-based vectors encoding either a well-
established anti-p53 shRNA (33) or, as a control for
oﬀ-target eﬀects, scrambled shRNA. After antibiotic
selection, stable clones, named UsiA (transfected with vec-
tors pSuper-p53 and pCI-neo), UsiB (transfected with
vector pENTR/H1-p53), and Scr (transfected with vector
pENTR/H1-src) were analyzed for mutp53 expression
by western blotting (Figure 5A). While the level of
1492 Nucleic Acids Research, 2009, Vol. 37,No. 5mutp53 in all clones expressing scrambled shRNA
remained unchanged, mutp53 expression was strongly
reduced in several clones selected after transfection with
anti-p53 shRNA-expressing constructs (Figure 5A). As
shown in Figure 5B, the amount of p53 transcripts was
signiﬁcantly reduced in the clones UsiA12, UsiB6, UsiB10
and UsiB23 in comparison to Scr1 and Scr2 clones expres-
sing scrambled shRNA. In line with this result, mutp53
nuclear staining typically observed for the parental cells
(Figure 5C) was dramatically reduced in anti-p53 shRNA-
expressing clones (UsiA12 clone shown as an example in
Figure 5D).
To study the consequences of mutp53 reduction on gene
expression, total RNA from UsiA12 and parental U251
cells was prepared from two independent cell culture
experiments (biological replicates) and processed for
microarray-based proﬁling of gene expression. A detailed
analysis of the microarray data will be presented elsewhere
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Figure 3. Content of repetitive DNA and S/MAR motifs in ChIP and random datasets. (A–B) Nucleotide sequences from the ChIP library, random
genomic fragments (2000 nucleotides centered on random positions) and random promoter regions (2-kb upstream of TSS) were analyzed for the
presence of repetitive elements and S/MAR motifs using RepeatMasker and Mar-Wiz web-tools, respectively. Although S/MARs are rather deﬁned
by functional tests than by sequence motifs, some sequence motifs can help to roughly identify the presence of S/MARs (38). The graphs show the
content of each class of repetitive sequences (A) and S/MAR-speciﬁc motifs (B) in all groups. Names of the repetitive sequences are marked under
the column graph. The content of the major classes of dispersed repetitive sequences is presented: Alu- and MIR-SINE, short interspersed nucleotide
element; LINE1, LINE2 and L3/CR1, long interspersed nucleotide element; MaLR, mammalian LTR retrovirus; ERVL, ERV_classI and
ERV_classII, endogenous retrovirus repeat family; MER1_type and MER2_type, medium reiteration frequency; simple repeats. The MAR-Wiz
tool was operated with its default settings (Ori rule, TG richness rule, curved-DNA rule, kinked-DNA rule, Topo II recognition rule, AT richness).
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for statistical signiﬁcance (P 0.05), we identiﬁed 805
genes whose mRNA levels were either increased (379
genes) or decreased (426 genes) >1.8-fold in both
UsiA12 replicates compared to parental U251 cells (see
Table S6). Assuming that some of the ChIP sequences
originate from diﬀerently regulated genes, we correlated
the ChIP results with the expression microarray data by
mapping the ChIP sequences to the genome. ChIP and
random sequences were inspected for their chromosomal
positions and proximity to known genes (UCSC and
Refseq gene tracks in Genome Browser, hg18). In total,
 49% of the analyzed ChIP sequences (71 out of 145)
were mapped to genes, mostly to introns and never close
to TSS (Figure 6; Table S2), whereas  37% of the
randomly selected genomic sequences (53 out of 145) are
derived from intra-genic regions (Figure 6; Table S7),
thereby indicating a tendency for a preferred location of
mutp53BS in intergenic regions. Inspection of the micro-
array expression proﬁles of the groups of genes to which
ChIP (Table S2) and random (Table S7) sequences were
mapped yielded two important observations: First, bind-
ing of p53
R273H was mainly associated with up-regulation
of the respective genes in UsiA12 cells (Figure 6). Since
mutp53 is down-regulated in UsiA12 cells, activation of
these genes in UsiA12 cells implies that these genes are
directly or indirectly repressed by mutp53 in parental
U251 cells. The mRNA amount of six out of seven regu-
lated genes, FRMD5, PPARGC1A, NRG1, C3ORF26,
TMEM108 and JAK2, was increased 1.8–4.4-fold in
UsiA12 cells (Table S2). Secondly, despite equal frequency
of mapping to active, non-regulated (‘on’) genes, two times
more ChIP sequences than random sequences mapped to
inactive (‘oﬀ’) genes (Figure 6). cis-Regulatory sequences
within the ﬁrst intron are the target sites for transcription
factors including p53 (62–64). We found that there is a
tendency for binding of mutp53 to sequences within the
ﬁrst intron (Figure 6). The location of ChIP sequences
within the ﬁrst introns of four genes up-regulated in
UsiA12 cells (i.e. repressed by mutp53 in U251 cells),
FRMD5, NRG1, C3ORF26 and JAK2, supports the signif-
icance of this observation.
Besides location in the ﬁrst intron, the proximity of
ChIP sequences in the genome might be indicative of
their functionality. Therefore we plotted the coordinates
of ChIP and random sequences using the ChromoMapper
program (37) and found a tendency for a local enrichment
of ChIP sequences at distinct chromosomal positions. The
distribution of ChIP sequences on chromosome 4 is shown
in Figure 7A (see Figure S3 for all chromosomes), illus-
trating that a signiﬁcant number of ChIP sequences (a
total of 42) localizes as closely linked pairs (duplets)
within a range of 2 Mb. One duplet (ChIP sequences
UC89 and UC98; Table S1) maps inside and close to the
PPARGC1A gene, up-regulated in UsiA12 cells, encoding
a transcriptional co-activator involved in controlling
energy metabolism (65); a second duplet (AB10 and
UC85; Table S1) localizes in an adjacent window of  2
Mb (Figure 7A). qRT–PCR analysis strongly supports
the assumption that the PPARGC1A gene is a transcrip-
tional target of mutp53. Indeed, in comparison to clones
expressing scrambled shRNA, the activity of the
PPARGC1A gene was signiﬁcantly aﬀected by anti-p53
shRNA in all four clones, resulting in 3–6-fold higher tran-
script levels (Figure 7B). Next, by qRT–PCR we measured
the expression of FRMD5, NRG1, C3ORF26 and JAK2 as
potential target genes regulated by mutp53 via binding to
cis-regulatory sequences within the ﬁrst intron. For the
FRMD5 gene, encoding a putative cytoskeletal protein,
we detected an up to 6-fold up-regulation in three anti-
p53 shRNA-expressing clones (Figure 7C). Thereby, we
identiﬁed two genes, PPARGC1A and FRMD5,a s
p53
R273H targets, whose transcription is down-regulated
either by binding of mutp53 to multiple sites that are
distant from the TSS (PPARGC1A) or to sequences
within the ﬁrst intron (FRMD5). However, transcription
AB7 AA3 AA12 AB23 pCRII
A
B
p53/DNA 
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Figure 4. Recombinant p53
R273H interacts preferentially with ChIP
DNA sequences in vitro.( A–B) Four selected ChIP DNA sequences
were tested for their interaction with p53
R273H using EMSA. For the
binding reaction, either PvuII-restriction fragments of empty or insert
containing pCRII vector (A), or supercoiled forms of plasmid DNA (B)
were used. Increasing amounts of p53
R273H protein (marked by p53/
DNA molar ratio) were incubated with 200ng of PvuII-restriction frag-
ments (A) or supercoiled DNA (B) in binding buﬀer and then separated
in an agarose gel. After staining with ethidium bromide, gels were
photographed. Restriction DNA fragments containing the multi-clon-
ing site and inserted ChIP sequences are marked by vertical arrows.
Positions of supercoiled forms (monomer and dimer) of plasmid DNA
after electrophoretic separation are marked by horizontal arrows.
Slowly migrating complexes of p53
R273H protein and supercoiled
DNA are marked by boxes.
1494 Nucleic Acids Research, 2009, Vol. 37,No. 5of the other tested genes was either regulated only in clone
Usi12A or indistinguishable from the control clones
(data not shown), indicating that mutp53-dependent regu-
lation of potential target genes may diﬀer in individual
U251 derived clones.
DISCUSSION
In the present work we provide evidence that mutp53,
speciﬁcally the R273H hot-spot mutant protein, is tar-
geted to the nucleus of U251 cells where it interacts with
DNA and participates in the regulation of gene transcrip-
tion. The R273H mutation in p53 disrupts the DNA-
binding surface and abolishes the speciﬁc interaction of
the core domain with wtp53 target nucleotide sequences
(66). However, it does not interfere with nuclear localiza-
tion and endows the protein with an increased half-life,
leading to its accumulation in the nucleus. In accordance
with FRAP measurements demonstrating that both
p53-GFP and mutp53-GFP (R273H, R175H) fusion pro-
teins overexpressed in p53-null H1299 cells undergo
constrained diﬀusion with similar kinetics within the
nucleus (67), we detected p53
R273H largely in the soluble
nuclear fraction which contains freely diﬀusing proteins.
Such a dynamic behavior seems to be a general phenom-
enon for transcription factors, which are predominantly
located in the non-bound fraction under steady-state con-
ditions, while only a small fraction is occupying DNA
target sites (68). It seems that p53
R273H shares this prop-
erty with wtp53 and other transcription factors. The small
fraction of p53
R273H bound to the detergent-insoluble
nuclear scaﬀold could represent proteins which at the
time of extraction were recruited to chromatin sites to
exert a regulatory function on gene transcription. The
retention of mutp53at the nuclear scaﬀold could be
mediated by interaction either with proteins or DNA
alone or by additive eﬀect of both interactions. Indeed,
our results point to a possibly direct interaction of
p53
R273H with components of the transcription machinery,
including the RNA polymerase II complex and the regu-
latory proteins Sp1 and YY1, known as binding partners
for wtp53 (50,51,69). On the other hand, EMSA studies
Figure 5. Stable reduction of p53
R273H expression using shRNA. (A) U251 cells were transfected with vectors encoding either anti-p53 or scrambled
shRNA, and after antibiotic selection, single clones (named as UsiA, UsiB and Scr) were tested by immunoblotting for the expression of mutp53.
Actin or HSC70 were used as a loading control. (B–D) Reduction of mutp53 expression in UsiA12 cells was validated by qRT–PCR (B) and
immunoﬂuorescence microscopy (C–D). (B) For relative quantitation of mutp53 transcription by qRT–PCR, total RNA from U251 clones expressing
either scrambled (Scr1 and Scr2) or p53-speciﬁc shRNA (UsiA12, UsiB6, UsiB10, UsiB23) was isolated three times. qRT–PCR was done in
triplicates. RQ (relative quantitation) values were calculated by normalizing to the transcription of the HPRT1 gene and selecting Scr1 sample as
calibrator. (C–D) Confocal images of U251 (C) and UsiA12 cells (D), immunostained with anti-p53 antibody (green). Z-stack sections were
deconvoluted using the Huygens software and the images were processed with the Imaris software. 3D reconstructed confocal images were
merged with a diﬀerential interference contrast (DIC) micrograph to show the cellular outlines and nuclei. Scale bar—15mm.
Nucleic Acids Research,2009, Vol.37, No. 5 1495using ChIP sequences support an association of p53
R273H
to chromatin by direct binding to DNA.
The bioinformatic evaluation of our ChIP sequencing
data conﬁrmed our assumption that the primary nucleo-
tide sequence of a mutp53-binding site would not be much
diﬀerent from any randomly selected genomic fragment,
since we presume that rather than its sequence, its location
in the genome and its conformational features would
determine its functionality. Consequently, the ChIP
DNA fragments are rich in repetitive DNA elements dis-
tributed more or less randomly over the whole genome
and are not enriched for any short nucleotide motif (e.g.
p53 response elements). Two lines of evidence argue
against the apparent random binding of p53
R273H to geno-
mic DNA: (i) over-representation of beta-satellite repeats
in the collection of the sequenced ChIP DNA fragments,
thereby qualifying p53
R273H as a beta-satellite binding
protein, and (ii) a signiﬁcant enrichment of ChIP
sequences over randomly selected sequences in inactive
genes or genes whose activity was enhanced after stable,
shRNA-mediated reduction of mutp53 expression.
According to these data it is likely that mutp53-binding
sites are largely located in transcriptionally inactive, con-
stitutive and facultative heterochromatin regions, repre-
sented by beta-satellite-rich DNA and inactive genes,
respectively. This would imply that the transcriptional
activity of mutp53 mainly, but not exclusively, results in
repressive eﬀects mediated by mutp53-dependent damping
of target gene transcription, or alternatively by gene
silencing or heterochromatization of the whole chromatin
domain. A likely prerequisite for such a role of mutp53 is
its ability to interact with repetitive DNA sequences,
whose role in gene regulation is well documented
(70,71). Importantly, repetitive DNA sequences contribute
to the fraction of non-B structured DNA (72,73), in this
way providing multiple binding sites for regulatory pro-
teins lacking sequence speciﬁcity, but endowed with the
capacity to sense DNA conformation. p53
R273H fulﬁlls
the criteria of a DNA-binding protein recognizing DNA
conformation, as it binds to non-linear DNA substrates,
but is virtually inactive toward linear DNA (6). In sup-
port, we detected a much stronger binding of p53
R273H to
non-linear DNA represented by a polypurine/polypyrimi-
dine tract than to other ‘linear’ ChIP DNA fragments.
Furthermore, p53
R273H bound signiﬁcantly better to
ChIP sequences inserted into supercoiled DNA than to
linearized plasmid DNA.
The mode of mutp53 DNA interaction in vitro (6)
allows us to hypothesize that in vivo mutp53 can bind
stably only to pre-existing non-B DNA structures, whose
real number and location depends on chromatin confor-
mation and composition, and cannot be predicted in silico
solely based on nucleotide sequence. Taking this into con-
sideration one would expect that mutp53 will bind with
low preference to multiple genomic regions representing a
fraction of potentially available sites. Indeed, quantifying
by sequence-speciﬁc real-time PCR the binding events of
mutp53 to ChIP sequences mapped to the ﬁrst introns,
Figure 6. Correlation of ChIP and expression microarray data. The graph shows the statistic evaluation of chromosomal positions of ChIP and
random genomic sequences which were inspected with respect to the coordinates of known genes (UCSC and Refseq gene tracks in Genome Browser,
hg18), location in the ﬁrst intron, transcriptionally regulated genes (up- or down-regulated in UsiA12 cells), and active (‘on’) or inactive (‘oﬀ’) gene as
judged from the expression microarray data (UsiA12 cells). Ordinate axis represents the percentage of sequences from both groups identiﬁed in each
analysis.
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genomic DNA (data not shown). The low speciﬁcity
would be compensated by the high abundance of
mutp53 in the nucleus, and the tendency for co-operative
binding and formation of higher-order oligomeric forms
(6). The latter notion is indirectly supported by Triton X-
100 extraction which results in multiple dot-like structures
decorated with p53 antibodies. The preference of mutp53
for one or the other genomic site could also be determined
by the local aﬃnity to the actual DNA structure and the
interaction with co-factors, for example, other DNA-bind-
ing proteins which could assist in recruitment of mutp53
to a particular site and co-operate in the transcriptional
activity of mutp53.
The ﬁnding that potential mutp53-binding sites lack
sequence speciﬁcity and are distributed over the whole
genome argues for a promoter-binding independent,
long-range mechanism for the regulation of gene
transcription by mutp53. Long-range regulation is not a
special attribute of mutp53, but reﬂects the notion that
transcription factors may act as dual-purpose regulators,
controlling gene expression either via direct targeting of a
gene or via (re)organizing higher-order chromatin struc-
ture. In this regard, recent genome-wide studies of the
binding of sequence-speciﬁc transcription factors (74),
including wtp53 (55), to DNA demonstrated that they
not only bind to regulatory sequences around TSS, but
also to numerous sites distributed over the whole
genome. Extending the term ‘epigenetics’ to regulatory
reactions primarily based on nuclear (re)organization,
including changes of the global chromatin conformation
(75,76) and the formation of new transcription factories
(46) in expense of existing ones, we want to propose that
mutp53 modulates the gene expression program as an epi-
genetic factor. In cooperation with other regulatory pro-
teins mutp53 might be involved in the establishment and
Figure 7. p53
R273H binding correlates with the regulation of PPARGC1A gene activity. (A) Chromosomal coordinates of ChIP and random
sequences on chromosome 4 were plotted using the ChromoMapper software. Closely linked positions of ChIP sequences in a window of 2 Mb
are marked by boxes. Genome browser snapshot shows the location of ChIP sequences in PPARGC1A gene. (B–C) Relative quantitation of
PPARGC1A (B) and FRMD5 (C) gene transcription by qRT–PCR. Total RNA from cell clones expressing scrambled (Scr1 and Scr2) or p53-
speciﬁc shRNA (UsiA12, UsiB6, UsiB10, UsiB23) was isolated three times. qRT–PCR was done in triplicates. Raw RQ values were calculated by
normalizing to the transcription of the HPRT1 gene and selecting Scr1 cell clone as calibrator.
Nucleic Acids Research,2009, Vol.37, No. 5 1497support of a transcription program. By binding to promo-
ter-distant, cis-regulatory sequences, for example within
the ﬁrst intron, mutp53 might inﬂuence chromatin orga-
nization which determines the transcriptional activity of a
particular gene. Our ChIP data support this hypothesis,
especially the identiﬁcation of four ChIP sequences from
non-coding regions inside and close to the PPARGC1A
gene, whose transcription was increased in all tested
clones with a reduced expression of mutp53. The connec-
tion between mutp53 and the transcriptional co-activator
PPARGC1A is interesting insofar, as low expression of
this protein in breast cancer patients was found associated
with poor clinical prognosis (77).
Correlation analyses performed for several tumor enti-
ties demonstrated that expression of mutp53 in human
tumors is associated with unfavorable prognosis (78).
Many mutp53 proteins, in particular all ‘hot spot’
mutp53 proteins, exert oncogenic functions which contrib-
ute to tumor progression. These functions appear in exper-
imental systems e.g. in enhanced growth rates and in the
modulation of the expression of tumor relevant genes
(79,80). Transcriptional regulation of such genes by
mutp53 has been demonstrated previously, and can be
achieved by an altered sequence-speciﬁcity of mutp53 pro-
teins (12), and by its interaction with other transcription
factors, like SP1, Ets1 and NF-Y (9–11). In this article we
describe another, more global mechanism for mutp53
dependent gene regulation which should also contribute
to its oncogenic functions. Although much more work
has to be done to understand the molecular details of
mutp53 activity, we believe that establishing an adequate
experimental cell model and applying genome-wide
technologies will help to expand our knowledge of tran-
scription in tumor cells in general, and the impact of
mutp53, in particular.
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